Lilly lowers 2019 forecast due to drug failure, pending deal
Drugmaker Eli Lilly revised its outlook due to the recently announced failure of the cancer treatment Lartruvo and a pending acquisition
INDIANAPOLIS – Shares of Eli Lilly slipped in early trading Wednesday after the drugmaker announced fourth-quarter earnings that missed Wall Street expectations and dropped its forecast for 2019.
Lilly says it revised its outlook due to the recently announced failure of the cancer treatment Lartruvo in a late-stage clinical trial and a pending acquisition. Lilly announced last month that it would spend about US$8 billion in cash to buy Loxo Oncology, as the drugmaker bulks up on cancer treatments that target certain gene abnormalities.
The company now expects 2019 adjusted earnings to range from $5.55 to $5.65 per share, down from a forecast it made in December for between $5.90 and $6 per share.
Analysts expect, on average, $5.70 per share, according to FactSet.
In the fourth quarter, the maker of the insulin Humalog posted $1.13 billion in net income, with earnings adjusted for one-time gains and costs of $1.33 per share. Revenue climbed 5 per cent to $6.44 billion.
The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.36 per share.
Shares of Eli Lilly and Co. slipped $1.93 to $118.50 in pre-market trading. The Indianapolis company’s stock has climbed 4 per cent since the beginning of the year, while the Standard & Poor’s 500 index has increased 9 per cent. The stock has climbed 55 per cent in the last 12 months.
Elements of this story were generated by Automated Insights
(http://automatedinsights.com/ap) using data from Zacks Investment